Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 16/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922875 | 0.82 | L3MBTL1 (0.48) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL9933095 | 0.81 | SMN1; SMN2 (0.49) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL13481172 | 0.81 | RAB9A (0.43) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL30509470 | 0.80 | CSNK1D (0.36) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15885917 | 0.80 | CSNK1D (0.36) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15885797 | 0.79 | BRAF (0.46) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL1554588 | 0.79 | CSNK1D (0.57) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL4309166 | 0.79 | KEAP1 (0.47) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL13874337 | 0.79 | HTR2A (0.44) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL15884446 | 0.79 | BRAF (0.45) | BRAFPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029158-A | EGFR inhibitors | 缆图药品公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025080784-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4214199-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| CN-116490503-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| WO-2014109414-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | 富士フイルム株式会社 (JP) | 2014-07-17 | — | — | WO | disclosed |
| WO-2011038261-A1 | HETEROCYCLIC KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1846391-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006084015-A2 | RAF INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK2A1 | MAPK13 587/4885CSNK1D 1/4885CSNK1E 6/4885 |
| US-20060189627-A1 | RAF inhibitor compounds and methods | BRAF, RAF1, ARAF | MAPK13 75/4885CSNK1D 892/4885CSNK1E 671/4885 |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | NPM1, NAP1L1, REN | MAPK13 1518/4885CSNK1D 941/4885CSNK1E 1304/4885 |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | BRAF, RAF1, ARAF | MAPK13 75/4885CSNK1D 892/4885CSNK1E 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.